Prostate Cancer

In an interview with Targeted Oncology, William J. Catalona, MD, reviewed the history of active surveillance in the prostate cancer space and how the practice has become more widespread in the United States.

Patients were diagnosed with prostate cancer at the expected average age with a majority of individuals diagnosed with stage 1 or 2 disease, and a significant minority presented with metastases.

In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the use of enzalutamide plus androgen deprivation therapy in metastatic hormone sensitive prostate cancer and how post-hoc findings from the ARCHES study can be applied to practice.

Tanya Dorff, MD, discusses the phase 1 study of chimeric antigen receptor T-cell therapy in patients with metastatic castration-resistant prostate cancer.

Clayton Lau, MD, discusses the consequences of patients delaying cancer screenings due to fears of COVID-19.

IS-002 was shown to be safe, well-tolerated, and allow for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy, according to findings from a phase 1 study.

Darolutamide plus androgen deprivation therapy and docetaxel was not associated with an increase in incidence or severity of adverse events versus androgen deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Data supporting prostate-specific antigen screening shows harm-benefit tradeoff to be more favorable with complementary approaches to quantifying overdiagnosis.

The safety profile of relugolix in patients with advanced prostate cancer has been demonstrated in the phase 3 HERO clinical trial.

Results from a post-hoc analysis of ARCHES showed that the enzalutamide plus ADT significantly improved survival, as well as key secondary end points, compared with placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Findings from a post-hoc analysis of the phase 3 ARAMIS clinical trial shows positive efficacy and consistent safety and tolerability with darolutamide in patients with nonmetastatic castration resistant prostate cancer, despite type of prior local therapy.

Patients with metastatic castration-resistant prostate cancer treated with darolutamide for more than 4 years tolerated well the adverse effects of the drug.

Niraparib in combination with abiraterone acetate, and prednisone resulted in a composite response in more than half of all patients.

Neal Shore, MD, FACS discusses results from a post-hoc analysis of the phase 3 ARCHES trial.

Use of 18F-rhPSMA-7.3 PET results in post-scan upstaging compared with conventional imaging in patients with prostate cancer recurrence.

Shawn Dason, MD, a urologic oncologist at The Ohio State University Comprehensive Cancer Center, discusses the decline of prostate cancer screening in recent years and how it has impacted care of patients with prostate cancer overall.

Production of lutetium Lu 177 vipivotide tetraxetan and Luthathera have been temporarily suspended due to potential quality issues identified in their manufacturing processes.

The FDA has accepted a supplemental new drug application for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer and granted it priority review.

Tanya Dorff, MD, discusses the recent findings from a phase 1 clinical trial which explored the use of chimeric antigen receptor T-cell therapy in patients with prostate cancer.

Results from the phase 3 ARCHES trial confirm the survival benefit of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

During a live virtual event, Matthew B. Rettig, MD, discussed the results of the TITAN trial of apalutamide for patients with metastatic castration-sensitive prostate cancer.

A recent study looked into where time-to-next therapy and overall survival with immune checkpoint inhibitors were longer compared with taxane therapy, in patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed the CARD trial of cabazitaxel and the VISION trial of lutetium-177 for patients with metastatic castration-resistant prostate cancer.

Scott Tagawa, MD, MS, FACP wraps up by discussing how he envisions the future of prostate cancer and offers advice to community oncologists treating patients with the disease.

An overview of the barriers and challenges that patients, caregivers, clinicians, and other healthcare personnel may face when radiation-based therapies are used for treatment of prostate cancer.

Scott Tagawa, MD, MS, FACP, discusses other prostate cancer settings besides metastatic CRPC where Lu 177 vipivotide tetraxetan could potentially be useful, and touches on ongoing clinical trials in these settings.

A discussion of key safety data on the VISION trial.

Scott Tagawa, MD, MS, FACP, compares the use of single-agent regimens versus combination regimens in the treatment of metastatic prostate cancer.

Scott Tagawa, MD, MS, FACP, reviews key efficacy data from the VISION trial of Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (CRPC).